Highest-materiality recent filing
MetLife declares Q2 2026 preferred stock dividends on Series A, E, F
Series A floating rate preferred: $0.31190376 per share, payable June 15, 2026.
MetLife Q1 2026 net income rises 30% to $1.1B, adjusted EPS up 23% to $2.42
Adjusted earnings up 18% to $1.6B driven by higher variable investment income and volume growth.
MetLife estimates Q1 2026 variable investment income $475M-$525M pre-tax; full-year guidance ~$1.6B
Estimates Q1 2026 variable investment income of $475M to $525M pre-tax (unaudited, preliminary).
MetLife confirms Q1 2026 Series A preferred dividend of $0.31501229/share
Preferred Series A dividend of $0.31501229 per share payable March 16, 2026.
MetLife issues $1B of 5.850% subordinated debentures due 2056
Issued $1B aggregate principal of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056.
MetLife expands board to 13, elects Daniel S. Glaser and Michelle R. Seitz as independent directors
Board increased from 11 to 13; Glaser and Seitz elected as independent directors effective Feb 24, 2026.
MetLife declares Q1 2026 preferred dividends; Series A subject to confirmation
Semi-annual dividend of $29.375/sh on Series D (5.875% fixed-to-floating, $1,000 liq. pref.).
FY2025 net income $3.2B ($4.71/sh); adjusted EPS ex notable items $8.89, up 10% YoY.
MetLife reorganizes segments: MIM becomes reportable, MetLife Holdings moved to Corporate & Other
Effective Q4 2025: MetLife Investment Management becomes a separate reportable segment, formerly in Corporate & Other.
MetLife closes PineBridge acquisition; combined AUM reaches $734.7B
Closed acquisition of PineBridge Investments on December 30, 2025, announced in December 2024.
Q4 2025 variable investment income estimated $385M–$435M pre-tax vs $425M target; FY 2025 private equity return ~7.7%.
MetLife completes $10B variable annuity risk transfer with Talcott Resolution
Transaction reinsures ~$10B of U.S. retail variable annuity and rider reserves with Talcott Resolution.
MetLife declares Q4 2025 preferred stock dividends on Series A, E, F
Series A (MET PRA): $0.33489390 per share, payable Dec. 15 to holders of record Nov. 28.
MetLife Q3 adj EPS $2.34 (+21% YoY); secured $12B PRT mandates in Q4-to-date
Adjusted earnings $1.6B ($2.37/diluted share); adjusted EPS ex-notable items $2.34 (+21% YoY).
MetLife eliminates Series G Preferred Stock designation after full redemption
Filed Certificate of Elimination with Delaware on October 14, 2025 to remove Series G Preferred Stock from charter.
MetLife: Q3 2025 variable investment income on track to meet $425M target
Q3 2025 variable investment income estimated at ~$425M pre-tax, consistent with full-year ~$1.7B guidance.
MetLife warns shareholders to reject unsolicited mini-tender offer at 34% below market
Potemkin offers $53.00/share for up to 10,000 MET shares, 34.42% below $80.82 closing price on Sept 12, 2025.
MetLife redeems all Series G Preferred Stock on Sept 15, 2025 at $1,000/share
Redemption of all outstanding 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G.
MetLife declares Q3 2025 preferred dividends on five series
Quarterly dividend of $0.35263005/sh on Series A floating-rate preferred (MET PRA).
MetLife Q2 adjusted EPS $2.02, down 11% YoY; net income $698M; PFOs ex-PRT up 5%
Adjusted earnings $1.36B ($2.02 EPS) vs $1.63B ($2.28) in 2Q24, down 16% (11% per share).
MetLife appoints Adrienne O'Neill as EVP and CAO, effective Sept 2, 2025
O'Neill joins from Manulife; most recently CFO of Asia Segment.
MetLife co-sponsors Chariot Re; transfers ~$10B in annuity liabilities to new reinsurer
Chariot Re, co-sponsored by MetLife and General Atlantic, will reinsure ~$10B of MetLife's structured settlement and pension risk transfer annuity contracts.
MetLife estimates Q2 2025 variable investment income between $175M and $225M pre-tax
Q2 2025 variable investment income estimated at $175M-$225M pre-tax, including private equity and real estate.
All 11 director nominees elected; top vote-getter Christian Mumenthaler (555.3M for), lowest Denise Morrison (522.7M for).
MetLife issues ¥87.84B in senior notes across six tranches due 2032-2055
Issued ¥87.84B aggregate principal of yen-denominated senior notes with coupons from 2.14% to 3.62%.
MetLife declares Q2 2025 preferred stock dividends payable June 16
Series A floating rate preferred: $0.35141735 per share.
MetLife Q1 net income up 10% to $879M; adjusted EPS $1.96 beats; new $3B buyback
Net income $879M ($1.28/diluted EPS), up 10% YoY; adjusted earnings $1.349B ($1.96/diluted), up 1% YoY.
MetLife to reinsure ~$10B in variable annuity reserves with Talcott; reduces tail risk 40%
Reinsurance agreement with Talcott covers ~$10B of U.S. retail variable annuity and rider reserves.
MetLife director David L. Herzog resigns from board effective May 1, 2025
David L. Herzog notified the Board of his resignation on March 27, 2025.
MetLife issues $1B of 6.350% subordinated debentures due 2055
Issued $1.0B aggregate principal of 6.350% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2055.
MetLife confirms Series A preferred dividend for Q1 2025
Series A preferred dividend confirmed at $0.35516415 per share for Q1 2025.
MetLife establishes $1.25B P-Caps facility with 5.740% Senior Notes due 2055
Trust issued 1.25M P-Caps for aggregate $1.25B; proceeds invested in U.S. Treasury strips.
MetLife appoints interim CAO and adds Christian Mumenthaler to board
Toby Srihiran Brown appointed interim Chief Accounting Officer, effective March 15, 2025, replacing departing Tamara L. Schock.
MetLife declares Q1 2025 preferred dividends; Series A subject to financial test confirmation
Series D semi-annual $29.375/share; Series E quarterly $0.3515625/depositary share; Series F quarterly $0.296875/depositary share; Series G semi-annual $19.250/share.
MetLife FY2024 net income $4.2B, EPS up 228%; raises adjusted ROE target to 15-17%
FY2024 net income of $4.2B ($5.94 EPS) vs $1.4B ($1.81) in 2023; adjusted EPS $8.15, up 12%.
MetLife CAO Tamara L. Schock resigns; last day March 14, 2025
Executive VP and Chief Accounting Officer Tamara L. Schock resigns to pursue another opportunity.
MetLife unveils New Frontier strategy targeting double-digit EPS growth, 15-17% ROE
New five-year strategy aims for double-digit adjusted EPS growth (from ~6%) and 15-17% adjusted ROE (from 12-14%).
MetLife and General Atlantic form Chariot Re; MetLife to cede ~$10B in annuity reserves
MetLife and General Atlantic each take ~15% equity in new Bermuda reinsurer Chariot Re; initial combined equity >$1B; Chubb as anchor third-party investor.
MetLife declares Q4 2024 preferred dividends on Series A, E, F
Series A: $0.39232690 per share; Series E: $351.5625 per share ($0.3515625 per depositary share); Series F: $296.875 per share ($0.296875 per depositary share).
MetLife Q3 adjusted EPS $1.95, down 1% YoY; net income surges to $1.3B on derivative gains
Net income $1.275B ($1.81 per share) vs $422M ($0.56) in Q3'23, up 202% on higher net derivative gains.
MetLife issues additional $250M 5.300% Senior Notes due 2034
Issued $250M additional aggregate principal of 5.300% Senior Notes due 2034 on Sept 30, 2024.
MetLife declares Q3 2024 preferred stock dividends on five series, payable Sept 16
Series A quarterly dividend $0.41713578 per share; Series D semi-annual $29.375 per share.
MetLife Q2 net income $912M ($1.28 EPS); adj EPS $2.28 beats $1.94; $0.9B buyback in Q2
Net income $912M ($1.28) vs $370M ($0.48) YoY; adjusted earnings $1.628B ($2.28) vs $1.492B ($1.94).
Shareholders approve MetLife 2025 Stock Plan, AVIP; all director nominees elected
Shareholders elected 13 directors: highest vote 603M for Laura Hay, lowest 575M for Cheryl Grise.
MetLife issues $500M of 5.300% Senior Notes due 2034
$500M aggregate principal, 5.300% fixed rate, maturing 2034, issued June 5, 2024.
MetLife declares Q2 2024 preferred stock dividends for Series A, E, F
Series A floating rate preferred: $0.43023800 per share, payable June 17, 2024.
MetLife Q1 net income $800M ($1.10 EPS), adj EPS $1.83; board approves $3B buyback
Net income $800M ($1.10 per share) vs $14M ($0.02) in Q1 2023; adjusted earnings $1.3B ($1.83 per share), up 20% YoY.
MetLife to redeem all £350M of 5.375% Senior Notes due Dec 2024 on Apr 11
Full redemption of £350 million outstanding principal of 5.375% Senior Notes due December 9, 2024.
MetLife issues ¥112.3B in seven tranches of senior notes with coupons ranging 1.009%-2.448%
Issued ¥7.1B of 1.009% Senior Notes due 2029, ¥23.1B of 1.415% due 2031, and five other tranches through 2059.
MetLife confirms Q1 2024 Series A preferred stock dividend of $0.42000544 per share
Dividend of $0.42000544 per share on floating rate non-cumulative preferred stock, Series A (MET PRA).
On March 27, 2025, David L. Herzog, a director of MetLife, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision to resign from the Board, effective May 1, 2025, and not to stand for re-election at the Company’s 2025 annual meeting of shareholders.
appointed Toby Srihiran Brown, Executive Vice President and Global Head of Reinsurance of the Company, as the Company’s interim Chief Accounting Officer, to be effective as of March 15, 2025
elected Christian Mumenthaler a director of the Company and appointed Mr. Mumenthaler to its Finance and Risk Committee and its Investment Committee, effective May 1, 2025.
Tamara L. Schock, notified the Company of her intent to resign as Executive Vice President and Chief Accounting Officer of the Company.
On January 7, 2025, Tamara L. Schock, Executive Vice President and Chief Accounting Officer of MetLife, Inc. (the “Company”), informed the Company that she would resign from her position to pursue another opportunity.
On February 27, 2024, the Board of Directors (the “Board”) of MetLife, Inc. (the “Company”) elected Laura J. Hay a director of the Company and appointed Ms. Hay to its Audit Committee and its Finance and Risk Committee, effective immediately.
Max materiality 0.90 · Median 0.53 · Most common event dividend